Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Zacatecas Silver closes first tranche of non-brokered private placement, raises $1.48 million at $0.07/unit

Zacatecas Silver closes first tranche of non-brokered private placement, raises $1.48 million at $0.07/unit

ReutersReuters2026/07/29 21:37
  • Zacatecas Silver closed a first tranche of a non-brokered private placement, issuing 21,074,201 units at $0.07 for gross proceeds of $1.48 million.
  • Each unit includes one common share plus a warrant exercisable at $0.09 for two years, with an expiry acceleration trigger at a $0.18 20-day VWAP.
  • Paid $66,934 in finder’s fees, issued 956,194 finder warrants exercisable at $0.09 for two years.
  • Proceeds earmarked for a maiden drill program at the Oso Negro project in Sonora, Mexico, plus broader exploration and working capital.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zacatecas Silver Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607291730PRIMZONEFULLFEED9800567) on July 29, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage